Clinical Trial Update: Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19) [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating how DZD9008 influences the pharmacokinetics of cocktail probe drugs reflecting CYP3A4, P-gp, BCRP, and OATP1B1 in patients with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Egfr-mutant Non-small Cell Lung Cancer
• Mutant Non-small Cell Lung Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• DZD9008

Snippet

Sponsor: Dizal Pharmaceuticals | Conditions: Non-small Cell Lung Cancer | Phase 1 | Status: COMPLETED